Resources

Novel Coronavirus (COVID-19) Vaccine Development – Wave 2

Given the recent uptick in COVID-19 cases in the US, many InCrowd panelists have been reporting that they do not expect things to return to normal until a vaccine is developed and disseminated. In order to deepen our understanding of the COVID-19 vaccine landscape, we surveyed infectious disease specialists across the country to get their perception and predictions on the efficacy, impact, and competitive landscape of COVID-19 vaccines.*

* Please note, views in this survey reflect opinions only as reported by responding physicians.

Methodology:

  • Method:
    • 12-Minute MicroSurvey via InCrowd
  • Crowds:
    • Infectious disease doctors
  • Sample Size:
    • n = 100
      • Community Hospital, Academic Hospital, Office-based
  • Fielding Period:
    • October 22nd – 26th

InCrowd’s other COVID-19 Tracking Reports:

Please fill out the form below to access this content

Name(Required)
This field is for validation purposes and should be left unchanged.

Related Resources

2023 Post-ESMO Excitement Report 

2023 Post-ESMO Excitement Report 

What Doctors thought of this year's ESMO Event Reaching European attendees, our 2023 Post-ESMO report sought to understand the event’s areas of greatest interest. 95 European oncologists and haematologist-oncologists shared with us the findings and developments they...

read more
Instant Insights – CRISPR

Instant Insights – CRISPR

Prescriber Perceptions around CRISPR in 2023 Four years ago, InCrowd assessed the awareness among physicians of nucleic acid-based therapies, their mechanisms of action, and their current and future promise.In considering the 2019 research, InCrowd wanted to...

read more
Instant Insights – Weight Loss Drugs

Instant Insights – Weight Loss Drugs

Prescriber Perspectives on Weight Loss Drugs in 2023 Examine how healthcare professionals (HCPs) view and prescribe weight loss drugs currently on the market in our new Instant Insights report. Fielded in a single day, this report includes responses from 100 qualified...

read more